Gone to pot–a review of the association between cannabis and psychosis

R Radhakrishnan, ST Wilkinson, DC D'Souza - Frontiers in psychiatry, 2014 - frontiersin.org
Cannabis is the most commonly used illicit drug worldwide, with~ 5 million daily users
worldwide. Emerging evidence supports a number of associations between cannabis and …

Human laboratory studies on cannabinoids and psychosis

M Sherif, R Radhakrishnan, DC D'Souza… - Biological …, 2016 - Elsevier
Some of the most compelling evidence supporting an association between cannabinoid
agonists and psychosis comes from controlled laboratory studies in humans. Randomized …

Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia

DC Javitt, M Lee, JT Kantrowitz, A Martinez - Schizophrenia research, 2018 - Elsevier
Mismatch negativity (MMN) is among the best established biomarkers of cortical dysfunction
in schizophrenia. MMN generators are localized primarily to primary and secondary auditory …

Clinical classification in mental health at the cross-roads: which direction next?

IB Hickie, J Scott, DF Hermens, EM Scott, SL Naismith… - BMC medicine, 2013 - Springer
Background After 30 years of consensus-derived diagnostic categories in mental health, it is
time to head in new directions. Those categories placed great emphasis on enhanced …

Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders

MB Sami, S Bhattacharyya - Journal of Psychopharmacology, 2018 - journals.sagepub.com
A substantial body of credible evidence has accumulated that suggest that cannabis use is
an important potentially preventable risk factor for the development of psychotic illness and …

[HTML][HTML] Use of cognitive event-related potentials in the management of psychiatric disorders: Towards an individual follow-up and multi-component clinical approach

S Campanella - World journal of psychiatry, 2021 - ncbi.nlm.nih.gov
Relapse prevention remains a major challenge in psychiatry, thus indicating that the
established treatment methods combining psychotherapy with neuropharmacological …

Longitudinal associations between mismatch negativity and disability in early schizophrenia-and affective-spectrum disorders

M Kaur, J Lagopoulos, RSC Lee, PB Ward… - Progress in Neuro …, 2013 - Elsevier
Background Impaired mismatch negativity (MMN) is a robust finding in schizophrenia and,
more recently, similar impairments have been reported in other psychotic-and affective …

Auditory mismatch detection, distraction, and attentional reorientation (MMN-P3a-RON) in neurological and psychiatric disorders: A review

E Justo-Guillén, J Ricardo-Garcell… - International Journal of …, 2019 - Elsevier
Involuntary attention allows for the detection and processing of novel and potentially
relevant stimuli that lie outside of cognitive focus. These processes comprise change …

Chronic effects of cannabis use on the auditory mismatch negativity

L Greenwood, SJ Broyd, R Croft, J Todd, PT Michie… - Biological …, 2014 - Elsevier
Background Cannabis use is associated with the development of psychotic symptoms and
increased risk for schizophrenia. The mismatch negativity (MMN) is a brain event-related …

Acute effects of Δ9-tetrahydrocannabinol and cannabidiol on auditory mismatch negativity

LM Greenwood, SJ Broyd, HH van Hell, J Todd… - …, 2022 - Springer
Rationale Mismatch negativity (MMN) is a candidate endophenotype for schizophrenia
subserved by N-methyl-D-aspartate receptor (NMDAR) function and there is increasing …